Compare AXT Inc (AXTI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AXT Inc vs Medpace Holdings Inc — how do they compare? AXT Inc trades at $57.53 (market cap $3.77B), while Medpace Holdings Inc trades at $536.29 (market cap $15.31B). The key difference: Medpace Holdings Inc is far larger — about 4.1× AXT Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, AXT Inc nearer its low. Which is the better fit depends on your goals.
| AXTI | MEDP | |
|---|---|---|
Market Cap | $3.77B | $15.31B |
Sector | Technology | Technology |
52-Week High | $140.83 | $620.59 |
52-Week Low | $1.92 | $308.88 |
Enterprise Value | $3.73B | $14.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXTI trades at $50.46, down 11.8% in the past 24 hours, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $21.26M in 2025 despite revenue of $88.33M, though 2026 projections show improved margins. Recent news highlights strong AI-driven demand for indium phosphide substrates and a $100M+ backlog, but export delays and cash flow risks remain concerns. Analyst consensus is bullish with 7 buy ratings, but technical indicators suggest near-term pressure.
The stock faces near-term headwinds from weak cash flow and high valuations (P/S 27.84), but long-term growth potential exists if AI demand materializes and capacity expansion executes smoothly. Key risks include geopolitical tensions affecting exports and execution challenges in scaling production. Investors should weigh the bullish analyst outlook against persistent fundamental weaknesses and technical bearishness.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
